Linked Life Data

15385809

Source:http://linkedlifedata.com/resource/pubmed/id/15385809

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-9-23
pubmed:abstractText
Induction with monoclonal antibodies for prevention of acute cellular rejection (ACR) may avoid many of the adverse events associated with polyclonal antibodies. Basiliximab, a chimeric monoclonal antibody directed against the alpha-chain of the interleukin 2 receptor (CD25), has been extensively evaluated as an induction therapy for kidney transplant recipients, more frequently in combination with a cyclosporine-based regimen. In this study, we assessed the efficacy and safety of basiliximab in combination with a tacrolimus-based regimen after liver transplantation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0041-1337
pubmed:author
pubmed:issnType
Print
pubmed:day
27
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
886-91
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
pubmed:affiliation
Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107-5083, USA. ignazio.marino@jefferson.edu
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial